Overland Park, KS – In a groundbreaking development, a recent peer-reviewed paper titled “Mesenchymal Stem Cell Extracellular Vesicles from Tissue-Mimetic System Enhance Epidermal Regeneration via Formation of Migratory Cell Sheets,” published on July 29, 2023, in the journal “Tissue Engineering and Regenerative Medicine,” offers open access to its findings. [Read more…]
Revolutionary Study Introduces Advanced Approach to Epidermal Regeneration Using Mesenchymal Stem Cell Secretome and Ronawk’s Bio-Blocks™
Overland Park, KS – A groundbreaking study titled “Tailoring the Secretome Composition of Mesenchymal Stem Cells to Augment Specific Functions of Epidermal Regeneration: An In Vitro Diabetic Model,” conducted by, Jacob G. Hodge, Ph.D., introduces a pioneering strategy to revolutionize epidermal regeneration using the secretome of mesenchymal stem cells (MSCs) utilizing Ronawk’s Bio-Blocks™. Published in June 2023 in the journal
“Frontiers in Medical Technology” and available through open access, the study unveils a powerful solution for optimizing wound healing, particularly in a diabetic context. [Read more…]
Axol Bioscience and StrataStem to Deliver iPSC-Derived ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.
CAMBRIDGE, England & EDINBURGH, Scotland — Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide range of brain cells, including neurons and neuroinflammatory cells. Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. [Read more…]
How Topical Application of Stem Cell Serum Can Reverse COVID-Induced Hair Loss
What is Covid-related hair loss?
Covid-19 is said to cause long-term side effects in up to 67% of patients, and these health consequences can include chronic fatigue, loss of taste and smell and brain fog. Increasingly common too is Covid-related hair loss. Known as telogen effluvium, this phenomenon manifests as clumps of hair falling out after brushing or washing your hair. [Read more…]
StemBioSys Launches CELLvo™, Human iPSC-Derived Atrial Cardiomyocytes for Cardiotoxicity Screening
Developed in collaboration with REPROCELL, CELLvo™Â Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells
SAN ANTONIO, June 13, 2023 — StemBioSys, Inc. (StemBioSys) announced the launch of CELLvo™Â Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™Â Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use. [Read more…]
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 201
- Next Page »